Patents by Inventor Osvaldo Flores

Osvaldo Flores has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combinations and methods comprising a capsid assembly inhibitor
    Patent number: 11129834
    Abstract: The present disclosure is directed to capsid assembly inhibitor compositions and methods for use in the treatment of hepatitis B virus infection.
    Type: Grant
    Filed: August 15, 2019
    Date of Patent: September 28, 2021
    Assignees: Novira Therapeutics, Inc., Janssen Sciences Ireland Unlimited Company
    Inventors: George Hartman, Osvaldo Flores, Klaus Klumpp, Man Iu Lam, Jan Martin Berke
  • COMBINATIONS AND METHODS COMPRISING A CAPSID ASSEMBLY INHIBITOR
    Publication number: 20190365767
    Abstract: The present disclosure is directed to capsid assembly inhibitor compositions and methods for use in the treatment of hepatitis B virus infection.
    Type: Application
    Filed: August 15, 2019
    Publication date: December 5, 2019
    Inventors: George Hartman, Osvaldo Flores, Klaus Klumpp, Man Iu Lam, Jan Martin Berke
  • Combinations and methods comprising a capsid assembly inhibitor
    Patent number: 10441589
    Abstract: The present disclosure is directed to capsid assembly inhibitor compositions and methods for use in the treatment of hepatitis B virus infection.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: October 15, 2019
    Assignees: NOVIRA THERAPEUTICS, INC., Janssen Sciences Ireland Unlimited Company
    Inventors: George Hartman, Osvaldo Flores, Klaus Klumpp, Man Iu Lam, Jan Martin Berke
  • Hepatitis B antiviral agents
    Patent number: 10196376
    Abstract: The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: February 5, 2019
    Assignee: NOVIRA THERAPEUTICS, INC.
    Inventors: George D. Hartman, Osvaldo A. Flores
  • COMBINATIONS AND METHODS COMPRISING A CAPSID ASSEMBLY INHIBITOR
    Publication number: 20170340642
    Abstract: The present disclosure is directed to capsid assembly inhibitor compositions and methods for use in the treatment of hepatitis B virus infection.
    Type: Application
    Filed: April 14, 2017
    Publication date: November 30, 2017
    Inventors: George HARTMAN, Osvaldo FLORES, Klaus KLUMPP, Man Iu LAM, Jan Martin BERKE
  • HEPATITIS B ANTIVIRAL AGENTS
    Publication number: 20170334882
    Abstract: The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.
    Type: Application
    Filed: June 2, 2017
    Publication date: November 23, 2017
    Inventors: George D. Hartman, Osvaldo A. Flores
  • Hepatitis B antiviral agents
    Patent number: 9751857
    Abstract: The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: September 5, 2017
    Assignee: NOVIRA THERAPEUTICS, INC.
    Inventors: George D. Hartman, Osvaldo A. Flores
  • Hepatitis B antiviral agents
    Patent number: 9676747
    Abstract: The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: June 13, 2017
    Assignee: NOVIRA THERAPEUTICS, INC.
    Inventors: George D. Hartman, Osvaldo A. Flores
  • HEPATITIS B ANTIVIRAL AGENTS
    Publication number: 20150259324
    Abstract: The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.
    Type: Application
    Filed: June 2, 2015
    Publication date: September 17, 2015
    Inventors: George D. Hartman, Osvaldo A. Flores
  • Hepatitis B antiviral agents
    Patent number: 9066932
    Abstract: The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: June 30, 2015
    Assignee: Novira Therapeutics, Inc.
    Inventors: George D. Hartman, Osvaldo A. Flores
  • Hepatitis B antiviral agents
    Patent number: 9061008
    Abstract: The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.
    Type: Grant
    Filed: December 9, 2013
    Date of Patent: June 23, 2015
    Assignee: Novira Therapeutics, Inc.
    Inventors: George D. Hartman, Osvaldo A. Flores
  • Hepatitis B Antiviral Agents
    Publication number: 20150152073
    Abstract: The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.
    Type: Application
    Filed: October 17, 2014
    Publication date: June 4, 2015
    Inventors: George D. Hartman, Osvaldo A. Flores
  • HEPATITIS B ANTIVIRAL AGENTS
    Publication number: 20140179665
    Abstract: The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.
    Type: Application
    Filed: December 9, 2013
    Publication date: June 26, 2014
    Inventors: George D. Hartman, Osvaldo A. Flores
  • HEPATITIS B ANTIVIRAL AGENTS
    Publication number: 20140178337
    Abstract: The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.
    Type: Application
    Filed: December 19, 2013
    Publication date: June 26, 2014
    Inventors: George D. Hartman, Osvaldo A. Flores
  • Hepatitis B antiviral agents
    Patent number: 8629274
    Abstract: The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: January 14, 2014
    Assignee: Novira Therapeutics, Inc.
    Inventors: George D. Hartman, Osvaldo A. Flores
  • HEPATITIS B ANTIVIRAL AGENTS
    Publication number: 20130251673
    Abstract: The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.
    Type: Application
    Filed: December 21, 2012
    Publication date: September 26, 2013
    Applicant: Novira Therapeutics, INC.
    Inventors: George D. HARTMAN, Osvaldo A. FLORES
  • HCV replicons containing NS5B from genotype 2B
    Patent number: 8354518
    Abstract: The present invention features methods for enhancing the ability of a genotype 2b NS5B sequence to function in a replicon, for producing replicons containing a functional genotype 2b NS5B, and for using replicons to measure the ability of a compound to affect HCV replication that is sustained with the genotype 2b polymerase. Also featured is a genotype 1b NS4B adaptive mutation. The ability to produce replicons containing a functional genotype 2b NS5B is illustrated by the production of chimeric replicons based on HCV genotype 1b where substantially all the NS5B sequence is replaced with a genotype 2b NS5B.
    Type: Grant
    Filed: November 3, 2004
    Date of Patent: January 15, 2013
    Assignees: Merck Sharp & Dohme Corp., Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A.
    Inventors: Steven W. Ludmerer, Donald J. Graham, Robert L. LaFemina, Osvaldo A. Flores, Maura Pizzuti, Cinzia Traboni
  • Hcv replicons containing ns5b from genotype 2b
    Publication number: 20110250628
    Abstract: The present invention features methods for enhancing the ability of a genotype 2b NS5B sequence to function in a replicon, for producing replicons containing a functional genotype 2b NS5B, and for using replicons to measure the ability of a compound to affect HCV replication that is sustained with the genotype 2b polymerase. Also featured is a genotype 1b NS4B adaptive mutation. The ability to produce replicons containing a functional genotype 2b NS5B is illustrated by the production of chimeric replicons based on HCV genotype 1b where substantially all the NS5B sequence is replaced with a genotype 2b NS5B.
    Type: Application
    Filed: November 3, 2004
    Publication date: October 13, 2011
    Inventors: Steven W. Ludmerer, Donald J. Graham, Robert L. Lafemina, Osvaldo A. Flores, Maura Pizzuti, Cinzia Traboni
  • Method to confer cell culture replication activity to different Hepatitis C virus isolates
    Patent number: 7807455
    Abstract: The present invention features methods for producing HCV replicons using HCV encoding sequences from different isolates. The featured methods are based on the discovered importance of NS3 amino acid position 470 in conferring cell culture replication activity to different HCV isolates.
    Type: Grant
    Filed: February 9, 2004
    Date of Patent: October 5, 2010
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jay Grobler, Osvaldo Flores, Eric J. Markel
  • Hepatitis C virus assay systems
    Patent number: 7786287
    Abstract: The present invention features assays employing a beta-lactamase reporter system, an HCV replicon enhanced cell, and/or a chimeric HCV replicon containing a 3? UTR based on the HCV-1a 3? UTR. These features can be employed alone or together, and are preferably combined together to measure HCV replicon activity and the affect of compounds on such activity.
    Type: Grant
    Filed: April 11, 2003
    Date of Patent: August 31, 2010
    Assignee: Merck & Co., Inc.
    Inventors: Osvaldo A. Flores, Jay Grobler, Edward M. Murray, Paul D. Zuck